JP2010280708A5 - - Google Patents

Download PDF

Info

Publication number
JP2010280708A5
JP2010280708A5 JP2010181380A JP2010181380A JP2010280708A5 JP 2010280708 A5 JP2010280708 A5 JP 2010280708A5 JP 2010181380 A JP2010181380 A JP 2010181380A JP 2010181380 A JP2010181380 A JP 2010181380A JP 2010280708 A5 JP2010280708 A5 JP 2010280708A5
Authority
JP
Japan
Prior art keywords
diabetic
disease
heart failure
aliskiren
hydrochlorothiazide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010181380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010280708A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010280708A publication Critical patent/JP2010280708A/ja
Publication of JP2010280708A5 publication Critical patent/JP2010280708A5/ja
Withdrawn legal-status Critical Current

Links

JP2010181380A 2002-05-17 2010-08-13 レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物 Withdrawn JP2010280708A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38154602P 2002-05-17 2002-05-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004505094A Division JP5288678B2 (ja) 2002-05-17 2003-05-16 レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物

Publications (2)

Publication Number Publication Date
JP2010280708A JP2010280708A (ja) 2010-12-16
JP2010280708A5 true JP2010280708A5 (https=) 2011-10-20

Family

ID=29550141

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004505094A Expired - Fee Related JP5288678B2 (ja) 2002-05-17 2003-05-16 レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物
JP2010181380A Withdrawn JP2010280708A (ja) 2002-05-17 2010-08-13 レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004505094A Expired - Fee Related JP5288678B2 (ja) 2002-05-17 2003-05-16 レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物

Country Status (24)

Country Link
US (3) US20050182042A1 (https=)
EP (2) EP1507558B8 (https=)
JP (2) JP5288678B2 (https=)
KR (3) KR20050008717A (https=)
CN (1) CN1655819A (https=)
AT (1) ATE520417T1 (https=)
AU (1) AU2003240669B2 (https=)
BR (1) BR0310084A (https=)
CA (1) CA2485081C (https=)
CY (2) CY1112013T1 (https=)
DK (1) DK1507558T3 (https=)
EC (1) ECSP045428A (https=)
ES (1) ES2369216T3 (https=)
IL (1) IL164837A (https=)
LU (1) LU92000I2 (https=)
MX (1) MXPA04011383A (https=)
NO (1) NO334382B1 (https=)
NZ (1) NZ536555A (https=)
PL (1) PL219032B1 (https=)
PT (1) PT1507558E (https=)
RU (1) RU2316318C2 (https=)
SI (1) SI1507558T1 (https=)
WO (1) WO2003097098A1 (https=)
ZA (1) ZA200408442B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DK1507558T3 (da) * 2002-05-17 2011-12-05 Novartis Pharma Ag Farmaceutisk sammensætning omfattende en renininhibitor, en calciumkanalblokker og et diuretikum
CA2525970C (en) 2003-05-15 2011-03-22 Roskamp Research, Llc Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
AR047880A1 (es) * 2004-02-17 2006-03-01 Novartis Ag COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS
NZ549535A (en) * 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders
MY148773A (en) * 2004-03-17 2013-05-31 Novartis Ag Galenic formulations of organic compounds
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
ATE474601T1 (de) * 2004-05-31 2010-08-15 Almirall Sa Kombinationen mit antimuskarin-wirkstoffen und pde4-hemmern
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
US20100240760A1 (en) * 2005-03-22 2010-09-23 Jessie Gu Biomarkers for Efficacy of Aliskiren as a Hypertensive Agent
RU2008122712A (ru) * 2005-11-08 2009-12-20 Новартис АГ (CH) Комбинация органических соединений
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
NZ577320A (en) * 2006-11-07 2012-01-12 Novartis Ag CRYSTALLINE FORMS OF ALISKIREN HEMIFUMARATE N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide
AR063597A1 (es) * 2006-11-09 2009-02-04 Novartis Ag Nueva sal
CA2708004C (en) * 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
WO2008098992A1 (en) * 2007-02-16 2008-08-21 Novartis Ag Use of organic compounds
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
RU2363472C2 (ru) * 2007-05-22 2009-08-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ профилактики и лечения кардиоваскулярных осложнений у больных с хронической болезнью почек, находящихся на гемодиализе, имеющих анурию
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
TWI500422B (zh) 2007-10-05 2015-09-21 Alzheimer S Inst Of America Inc 以（－）－尼代地平（ｎｉｌｖａｄｉｐｉｎｅ）對映異構物減低類澱粉沉積、類澱粉神經毒性及微神經膠細胞增生之方法
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
RU2373932C1 (ru) * 2008-05-20 2009-11-27 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при артериальной гипертонии
RU2372079C1 (ru) * 2008-05-20 2009-11-10 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при артериальной гипертонии, дислипидемии и нарушении толерантности к глюкозе
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
RU2382644C1 (ru) * 2008-11-05 2010-02-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
CA2755047C (en) * 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
PT2405928T (pt) * 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
EP2987803B1 (en) 2009-06-17 2018-08-29 Promedior Inc. Sap variants and their use
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN102552277A (zh) * 2011-12-02 2012-07-11 邬林祥 氨氯地平、阿利可仑和氢氯噻嗪复方降压药物
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
GB201317373D0 (en) 2013-10-01 2013-11-13 Univ Dundee Treatment and prevention of cancer
CN111789843A (zh) * 2019-04-08 2020-10-20 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物
KR102414285B1 (ko) * 2020-06-02 2022-06-28 이화여자대학교 산학협력단 플루나리진 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350771A (en) * 1989-03-22 1994-09-27 Peter K. T. Pang Method and treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers
AU656551B2 (en) * 1990-12-14 1995-02-09 Smithkline Beecham Corporation Angiotensin II receptor blocking compositions
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
US5178877A (en) * 1991-01-04 1993-01-12 Abbott Laboratories Encapsulated renin inhibitor composition
US5114925A (en) * 1991-01-22 1992-05-19 Merck & Co., Inc. Renin inhibitors containing the 2-[[(2R,3S)-3-amino-4-cyclohexyl-2-hydroxy-1-butyl]thio)alkanoyl moiety and the corresponding sulfoxide and sulfone derivatives
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040087484A1 (en) * 2000-12-01 2004-05-06 Sahota Pritam Singh Combination of organic compounds
EP1426051B1 (en) * 2001-09-11 2008-07-16 Asahi Kasei Pharma Corporation Medicinal composition for prevention of or treatment for cerebrovascular disorder
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
DK1507558T3 (da) * 2002-05-17 2011-12-05 Novartis Pharma Ag Farmaceutisk sammensætning omfattende en renininhibitor, en calciumkanalblokker og et diuretikum

Similar Documents

Publication Publication Date Title
JP2010280708A5 (https=)
RU2004137104A (ru) Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик
NO2016009I2 (no) Sakubitril/valsartan, inkludert farmasøytisk akseptable salter derav
JP2008530101A5 (https=)
WO2007106708A3 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
RU2004137105A (ru) Комбинация органических соединений
JP2005526850A5 (https=)
WO2007045663A3 (en) Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
RU2001102585A (ru) Гипотензивная комбинация валсартана и блокатора кальциевых каналов
CN1312715A (zh) 缬沙坦和钙通道阻断剂的抗超敏组合
EP1951309A2 (en) Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
FI3524250T3 (fi) Neutraalia endopeptidaasin (nep) estäjää ja atsilsartaaniesterijohdannaista sisältävä farmaseuttinen koostumus ja sen käyttö sydän- ja verisuonitautien hoitoon
RU2006144809A (ru) Комбинация органических соединений